Founder and CEO, Lighter Capital
President and CEO of the Central Indiana Corporate Partnership
Founder and Chairman, Sycamore Networks
Founder, Gilt Groupe
CEO and co-founder of BoostSuite
Director, Silicon Flatirons Centers' Entrepreneurship Initiative
Co-Founder and CEO, DNAnexus
These are heady times for neuroscience research. Startups developing new approaches to brain disorders are raising money to advance their discoveries toward clinical trials. One failed neuro drug is getting another shot.
On Nov. 19 in San Francisco, we’ll... Read more »
During the state of the union address this year, President Trump pledged to end HIV transmission within the next decade. A key part of that plan is an HIV prevention drug made by Gilead Sciences. That drug has now become the... Read more »
AstraZeneca says it will establish centers for drug research and artificial intelligence development in China. The pharmaceutical giant has also set up a $1 billion fund to foster biotech innovation in that country.
The move—which was announced at the China International... Read more »
The doors have opened at a GE Healthcare-supported open-access lab for startups at AstraZeneca’s former global center for oncology research and development at Alderley Park, the largest bioscience research campus in the UK.
The AstraZeneca (NYSE: AZN) site in Macclesfield,... Read more »
The brain has stymied many efforts to develop new neuroscience drugs, leading a number of big pharmaceutical companies to pull back on such R&D work. This week, Amgen joined them.
Amgen (NASDAQ: AMGN) is ending its research and early development... Read more »
Novartis must stop enrollment of a clinical trial testing its gene therapy for a rare, muscular disorder after safety concerns surfaced in data from an animal study.
The FDA put a partial clinical hold on a Phase 1/2 study testing the... Read more »
Earlier this year, it seemed that companies testing Alzheimer’s disease treatments based on a long-held hypothesis as to its cause—brain deposits of a protein called beta amyloid—were giving up the ghost.
Biogen (NASDAQ: BIIB) was among them. The drug maker... Read more »
New brand-name drugs typically grab the life science headlines. A venture capital firm will invest tens of millions to develop one and a pharmaceutical company hopes to recoup hundreds of millions by selling it. But a shortage of one particular chemotherapy... Read more »
Eli Lilly won FDA approval for a migraine drug on Friday, giving the pharmaceutical giant a second medication that addresses the condition that causes millions of people to experience severe headaches and other debilitating symptoms.
The FDA approved the drug, lasmiditan... Read more »
Congrats to this year’s Nobel Prize winners in medicine… although, we have to ask: For the US researchers who are honored, isn’t there something crushing about a call in the middle of the night from Sweden, interrupting a dream about... Read more »
Sixteen years ago, Kim Witczak’s husband died by his own hand, turning her world upside down. He had just begun taking an antidepressant off-label for insomnia, and she believes an undisclosed side effect of the drug drove him to suicide. Compelled... Read more »
Five years ago, the big tech incubator Y Combinator started to welcome life sciences companies into its sizable startup classes, which had previously nurtured entrepreneurs in information technology almost exclusively.
That opening to biotech startups in 2014 was controversial at the... Read more »
Oxygen’s importance in cellular processes has long been known. But the work to understand how cells sense and adapt to changes in oxygen levels has led to medical insights and potential treatments for anemia, cancer, and more—and today, it has turned... Read more »
This summer Nestlé Health Science sold Prometheus Laboratories, a gastrointestinal disease diagnostics unit it had acquired eight years prior, to a low-profile San Diego biotech called Precision IBD.
About a month ago, Precision—a drug and diagnostic developer that’s focused, as... Read more »
It’s been a strange up and down ride for PARP inhibitors, a relatively new class of cancer drugs.
Named for the tumor protein they target, PARPs rebounded after a big clinical setback in 2011 and have been at the center of... Read more »
The European Society for Medical Oncology meeting has wrapped up in Barcelona, the last major clinical cancer conference until December’s annual ASH meeting for blood diseases. We’ve highlighted a few top stories for you.
Amid all the fuss over cell, gene,... Read more »
In the past three years, Dova Pharmaceuticals has completed a company launch, gone public, and won its first drug approval. Now the biotech is in line to be acquired by Swedish Orphan Biovitrum (Sobi).
According to deal terms announced Monday, Dova... Read more »
Lung injuries linked to electronic cigarettes have topped 800 cases, including 12 deaths, according to the Centers for Disease Control and Prevention. Public health officials aren’t sure whether the injuries are from legally sold products made by companies such as... Read more »
Boston, San Francisco, and a few other metro areas might dominate the US life sciences, but some weeks, all bio-related eyes are on the nation’s capital. Health concerns about vaping continue to mount, and the feds could get involved. Meanwhile, try... Read more »
With the 2020 election just over a year away, House Speaker Nancy Pelosi (D-CA) has unveiled the Democratic Party’s answer to public discontent over high prescription drug prices.
A preview of the plan was leaked last week. Today’s announcement doesn’t... Read more »
For decades, advanced lung cancer was a quick death sentence. That’s no longer a given, thanks in part to the arrival of immunotherapy. If a medical meeting in Barcelona this week was any indication, more help could be on the... Read more »
The first details of the long-awaited House Democrat plan to lower drug prices leaked out Monday night, with elements that have long been anathema to the biopharma industry and its supporters in Washington.
While the world digested the details Tuesday, however,... Read more »
Sponsored · Whitepaper
What the most successful life sciences fundraising pitch decks all have in common
Brex
Xconomy Insight · Special Report
Insights, wisdom, and inspiration on what it takes
From Our Editors · Special Report
Key indicators & expert insight from industry leaders
Xconomy
CEO of G1 Therapeutics
Managing Partner at Pappas Ventures
CEO and co-founder of BoostSuite
Founder and CEO of Brooks Bell Inc.
President of the Council for Economic Development (CED)
Vice Provost and Director of the Innovation and Entrepreneurship Initiative at Duke University
Professor at the University of North Carolina at Chapel Hill
Retired CEO of ShopperTrak RCT Corporation
CEO of the Marine Bio-Technologies Center of Innovation
President, CEO, and Chairman of the Board of SciQuest
Vice President, Carolinas HealthCare System
Xconomy offers a number of ways to subscribe for free!
Subscribe Now
